Back to top

Image: Shutterstock

Top Ranked Value Stocks to Buy for November 9th

Read MoreHide Full Article

Here are four stocks with buy rank and strong value characteristics for investors to consider today, November 9th:

Danaos Corporation (DAC - Free Report) : This containerships owner and operator has a Zacks Rank #1 (Strong Buy), and seen the Zacks Consensus Estimate for its current year earnings rising nearly 14% over the last 60 days.

 

Danaos Corp has a price-to-earnings ratio (P/E) of 1.33, compared with 3.40 for the industry. The company possesses a Value Score of A.

 

Danaos Corporation PE Ratio (TTM)

Danaos Corporation PE Ratio (TTM)

Danaos Corporation pe-ratio-ttm | Danaos Corporation Quote

 

Equitable Holdings, Inc. (EQH - Free Report) : This diversified financial services company has a Zacks Rank #1, and seen the Zacks Consensus Estimate for its current year earnings rising 4.4% over the last 60 days.

 

Equitable Holdings has a price-to-earnings ratio (P/E) of 4.97, compared with 19.00 for the industry. The company possesses a Value Score of A.

 

Nomura Holdings, Inc. (NMR - Free Report) : This financial services provider has a Zacks Rank #1, and seen the Zacks Consensus Estimate for its current year earnings rising 19.8% over the last 60 days.

 

Nomura Holdings has a price-to-earnings ratio (P/E) of 4.97, compared with 12.20 for the industry. The company possesses a Value Score of B.

 

Western Asset Mortgage Capital Corporation (WMC - Free Report) : This real estate investment trust has a Zacks Rank #1, and seen the Zacks Consensus Estimate for its current year earnings rising 2% over the last 60 days.

 

Western Asset Mortgage Capital has a price-to-earnings ratio (P/E) of 4.22, compared with 7.20 for the industry. The company possesses a Value Score of A.

 

See the full list of top ranked stocks here.

Learn more about the Value score and how it is calculated here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>